Background: Homologous recombination deficiencies (HRD) are present in approximately half of epithelial ovarian cancers. for which PARP inhibitors (PARPi) are becoming a preferred treatment option. However. a considerable proportion of these carcinomas acquire resistance or harbour de novo resistance. https://www.jungleoasisplayground.com/product-category/industrialrestaurant-business-7/